{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:54:55Z","timestamp":1794567295253,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":105,"publisher":"Springer New York","isbn-type":[{"value":"9781493978243","type":"print"},{"value":"9781493978250","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7825-0_18","type":"book-chapter","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T08:44:16Z","timestamp":1527756256000},"page":"397-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessing and Modulating Kynurenine Pathway Dynamics in Huntington\u2019s Disease: Focus on Kynurenine 3-Monooxygenase"],"prefix":"10.1007","author":[{"given":"Korrapati V.","family":"Sathyasaikumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schwarcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaviano","family":"Giorgini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"18_CR1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.6849138","volume":"219","author":"R Schwarcz","year":"1983","unstructured":"Schwarcz R, Whetsell WO Jr, Mangano RM (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219:316\u2013318","journal-title":"Science"},{"key":"18_CR2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(81)90587-2","volume":"72","author":"TW Stone","year":"1981","unstructured":"Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72:411\u2013412","journal-title":"Eur J Pharmacol"},{"key":"18_CR3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0891-5849(03)00317-4","volume":"35","author":"A Santamar\u00eda","year":"2003","unstructured":"Santamar\u00eda A, Flores-Escartin A, Martinez JC et al (2003) Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems. Free Radic Biol Med 35:418\u2013427","journal-title":"Free Radic Biol Med"},{"key":"18_CR4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/321168a0","volume":"321","author":"MF Beal","year":"1986","unstructured":"Beal MF, Kowall NW, Ellison DW et al (1986) Replication of the neurochemical characteristics of Huntington\u2019s disease by quinolinic acid. Nature 321:168\u2013171","journal-title":"Nature"},{"key":"18_CR5","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/0003-9861(92)90733-D","volume":"294","author":"T Ishii","year":"1992","unstructured":"Ishii T, Iwahashi H, Sugata R et al (1992) Formation of hydroxanthommatin-derived radical in the oxidation of 3-hydroxykynurenine. Arch Biochem Biophys 294:616\u2013622","journal-title":"Arch Biochem Biophys"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/carcin\/16.2.349","volume":"16","author":"Y Hiraku","year":"1995","unstructured":"Hiraku Y, Inoue S, Oikawa S et al (1995) Metal-mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites. Carcinogenesis 16:349\u2013356","journal-title":"Carcinogenesis"},{"key":"18_CR7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0006-8993(89)90216-3","volume":"495","author":"CL Eastman","year":"1989","unstructured":"Eastman CL, Guilarte TR (1989) Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res 495:225\u2013231","journal-title":"Brain Res"},{"key":"18_CR8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/BF01101711","volume":"15","author":"CL Eastman","year":"1990","unstructured":"Eastman CL, Guilarte TR (1990) The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res 15:1101\u20131107","journal-title":"Neurochem Res"},{"key":"18_CR9","doi-asserted-by":"crossref","first-page":"12553","DOI":"10.1073\/pnas.93.22.12553","volume":"93","author":"S Okuda","year":"1996","unstructured":"Okuda S, Nishiyama N, Saito H et al (1996) Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci U S A 93:12553\u201312558","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18_CR10","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1046\/j.1460-9568.1999.00806.x","volume":"11","author":"P Guidetti","year":"1999","unstructured":"Guidetti P, Schwarcz R (1999) 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 11:3857\u20133863","journal-title":"Eur J Neurosci"},{"key":"18_CR11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.semcdb.2015.03.002","volume":"40","author":"DC Maddison","year":"2015","unstructured":"Maddison DC, Giorgini F (2015) The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol 40:134\u2013141","journal-title":"Semin Cell Dev Biol"},{"key":"18_CR12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0006-8993(82)91048-4","volume":"247","author":"MN Perkins","year":"1982","unstructured":"Perkins MN, Stone TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247:184\u2013187","journal-title":"Brain Res"},{"key":"18_CR13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0022-3565(24)37160-5","volume":"283","author":"CG Parsons","year":"1997","unstructured":"Parsons CG, Danysz W, Quack G et al (1997) Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 283:1264\u20131275","journal-title":"J Pharmacol Exp Ther"},{"key":"18_CR14","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","volume":"21","author":"C Hilmas","year":"2001","unstructured":"Hilmas C, Pereira EF, Alkondon M et al (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463\u20137473","journal-title":"J Neurosci"},{"key":"18_CR15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ntt.2011.07.002","volume":"33","author":"R Lugo-Huitr\u00f3n","year":"2011","unstructured":"Lugo-Huitr\u00f3n R, Blanco-Ayala T, Ugalde-Muniz P et al (2011) On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol 33:538\u2013547","journal-title":"Neurotoxicol Teratol"},{"key":"18_CR16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00702-011-0763-x","volume":"119","author":"F Moroni","year":"2012","unstructured":"Moroni F, Cozzi A, Sili M et al (2012) Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm 119:133\u2013139","journal-title":"J Neural Transm"},{"key":"18_CR17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2016.06.020","volume":"112","author":"F Fazio","year":"2017","unstructured":"Fazio F, Lionetto L, Curto M et al (2017) Cinnabarinic acid and xanthurenic acid: two kynurenine metabolites that interact with metabotropic glutamate receptors. Neuropharmacology 112:365\u2013372","journal-title":"Neuropharmacology"},{"key":"18_CR18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tips.2012.09.006","volume":"34","author":"TW Stone","year":"2013","unstructured":"Stone TW, Stoy N, Darlington LG (2013) An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci 34:136\u2013143","journal-title":"Trends Pharmacol Sci"},{"key":"18_CR19","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.3390\/ijms16059772","volume":"16","author":"Z Bohar","year":"2015","unstructured":"Bohar Z, Toldi J, F\u00fcl\u00f6p F et al (2015) Changing the face of kynurenines and neurotoxicity: therapeutic considerations. Int J Mol Sci 16:9772\u20139793","journal-title":"Int J Mol Sci"},{"key":"18_CR20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0304-3940(92)90749-W","volume":"144","author":"SJ Pearson","year":"1992","unstructured":"Pearson SJ, Reynolds GP (1992) Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington\u2019s disease. Neurosci Lett 144:199\u2013201","journal-title":"Neurosci Lett"},{"key":"18_CR21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","volume":"17","author":"P Guidetti","year":"2004","unstructured":"Guidetti P, Luthi-Carter RE, Augood SJ et al (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington\u2019s disease. Neurobiol Dis 17:455\u2013461","journal-title":"Neurobiol Dis"},{"key":"18_CR22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","volume":"112","author":"CM Forrest","year":"2010","unstructured":"Forrest CM, Mackay GM, Stoy N et al (2010) Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington\u2019s disease. J Neurochem 112:112\u2013122","journal-title":"J Neurochem"},{"key":"18_CR23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","volume":"93","author":"N Stoy","year":"2005","unstructured":"Stoy N, Mackay GM, Forrest CM et al (2005) Tryptophan metabolism and oxidative stress in patients with Huntington\u2019s disease. J Neurochem 93:611\u2013623","journal-title":"J Neurochem"},{"key":"18_CR24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-3940(00)00956-3","volume":"283","author":"P Guidetti","year":"2000","unstructured":"Guidetti P, Reddy PH, Tagle DA et al (2000) Early kynurenergic impairment in Huntington\u2019s disease and in a transgenic animal model. Neurosci Lett 283:233\u2013235","journal-title":"Neurosci Lett"},{"key":"18_CR25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","volume":"23","author":"P Guidetti","year":"2006","unstructured":"Guidetti P, Bates GP, Graham RK et al (2006) Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 23:190\u2013197","journal-title":"Neurobiol Dis"},{"key":"18_CR26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1471-4159.2010.06675.x","volume":"113","author":"KV Sathyasaikumar","year":"2010","unstructured":"Sathyasaikumar KV, Stachowski EK, Amori L et al (2010) Dysfunctional kynurenine pathway metabolism in the R6\/2 mouse model of Huntington\u2019s disease. J Neurochem 113:1416\u20131425","journal-title":"J Neurochem"},{"key":"18_CR27","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1074\/jbc.M708192200","volume":"283","author":"F Giorgini","year":"2008","unstructured":"Giorgini F, M\u00f6ller T, Kwan W et al (2008) Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem 283:7390\u20137400","journal-title":"J Biol Chem"},{"key":"18_CR28","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng1542","volume":"37","author":"F Giorgini","year":"2005","unstructured":"Giorgini F, Guidetti P, Nguyen Q et al (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 37:526\u2013531","journal-title":"Nat Genet"},{"key":"18_CR29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","volume":"21","author":"S Campesan","year":"2011","unstructured":"Campesan S, Green EW, Breda C et al (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington\u2019s disease. Curr Biol 21:961\u2013966","journal-title":"Curr Biol"},{"key":"18_CR30","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.bbagen.2016.07.002","volume":"1860","author":"PB Larkin","year":"2016","unstructured":"Larkin PB, Sathyasaikumar KV, Notarangelo FM et al (2016) Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice. Biochim Biophys Acta 1860:2345\u20132354","journal-title":"Biochim Biophys Acta"},{"key":"18_CR31","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1073\/pnas.1604453113","volume":"113","author":"C Breda","year":"2016","unstructured":"Breda C, Sathyasaikumar KV, Sograte Idrissi S et al (2016) Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proc Natl Acad Sci U S A 113:5435\u20135440","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18_CR32","doi-asserted-by":"crossref","first-page":"14912","DOI":"10.1073\/pnas.1203083109","volume":"109","author":"AT Goot van der","year":"2012","unstructured":"van der Goot AT, Zhu W, Vazquez-Manrique RP et al (2012) Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc Natl Acad Sci U S A 109:14912\u201314917","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18_CR33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molmed.2013.02.007","volume":"19","author":"AT Goot van der","year":"2013","unstructured":"van der Goot AT, Nollen EA (2013) Tryptophan metabolism: entering the field of aging and age-related pathologies. Trends Mol Med 19:336\u2013344","journal-title":"Trends Mol Med"},{"key":"18_CR34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JHD-159003","volume":"4","author":"G Mazarei","year":"2015","unstructured":"Mazarei G, Leavitt BR (2015) Indoleamine 2,3 dioxygenase as a potential therapeutic target in Huntington\u2019s disease. J Huntingtons Dis 4:109\u2013118","journal-title":"J Huntingtons Dis"},{"key":"18_CR35","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/jnc.12350","volume":"127","author":"G Mazarei","year":"2013","unstructured":"Mazarei G, Budac DP, Lu G et al (2013) Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. J Neurochem 127:852\u2013867","journal-title":"J Neurochem"},{"key":"18_CR36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.drudis.2014.11.007","volume":"20","author":"CJ Austin","year":"2015","unstructured":"Austin CJ, Rendina LM (2015) Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discov Today 20:609\u2013617","journal-title":"Drug Discov Today"},{"key":"18_CR37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4161\/fly.19999","volume":"6","author":"EW Green","year":"2012","unstructured":"Green EW, Campesan S, Breda C et al (2012) Drosophila eye color mutants as therapeutic tools for Huntington disease. Fly (Austin) 6:117\u2013120","journal-title":"Fly (Austin)"},{"key":"18_CR38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"D Zwilling","year":"2011","unstructured":"Zwilling D, Huang SY, Sathyasaikumar KV et al (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145:863\u2013874","journal-title":"Cell"},{"key":"18_CR39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.expneurol.2016.05.005","volume":"282","author":"V Beaumont","year":"2016","unstructured":"Beaumont V, Mrzljak L, Dijkman U et al (2016) The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington\u2019s disease. Exp Neurol 282:99\u2013118","journal-title":"Exp Neurol"},{"key":"18_CR40","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/schbul\/sbq112","volume":"37","author":"KV Sathyasaikumar","year":"2011","unstructured":"Sathyasaikumar KV, Stachowski EK, Wonodi I et al (2011) Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 37:1147\u20131156","journal-title":"Schizophr Bull"},{"key":"18_CR41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","volume":"130","author":"D Jauch","year":"1995","unstructured":"Jauch D, Urbanska EM, Guidetti P et al (1995) Dysfunction of brain kynurenic acid metabolism in Huntington\u2019s disease: focus on kynurenine aminotransferases. J Neurol Sci 130:39\u201347","journal-title":"J Neurol Sci"},{"key":"18_CR42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF01276566","volume":"102","author":"SJ Pearson","year":"1995","unstructured":"Pearson SJ, Meldrum A, Reynolds GP (1995) An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington\u2019s disease. J Neural Transm Gen Sect 102:67\u201373","journal-title":"J Neural Transm Gen Sect"},{"key":"18_CR43","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1073\/pnas.85.11.4079","volume":"85","author":"R Schwarcz","year":"1988","unstructured":"Schwarcz R, Okuno E, White RJ et al (1988) 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc Natl Acad Sci U S A 85:4079\u20134081","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18_CR44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0006-8993(85)90647-X","volume":"336","author":"AC Foster","year":"1985","unstructured":"Foster AC, Whetsell WO Jr, Bird ED et al (1985) Quinolinic acid phosphoribosyltransferase in human and rat brain: activity in Huntington's disease and in quinolinate-lesioned rat striatum. Brain Res 336:207\u2013214","journal-title":"Brain Res"},{"key":"18_CR45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ncpneuro0355","volume":"2","author":"NJ Maragakis","year":"2006","unstructured":"Maragakis NJ, Rothstein JD (2006) Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2:679\u2013689","journal-title":"Nat Clin Pract Neurol"},{"key":"18_CR46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hbm.21008","volume":"32","author":"M Politis","year":"2011","unstructured":"Politis M, Pavese N, Tai YF et al (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2019s disease: a multimodal imaging study. Hum Brain Mapp 32:258\u2013270","journal-title":"Hum Brain Mapp"},{"key":"18_CR47","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1042\/BST20140107","volume":"42","author":"A Verkhratsky","year":"2014","unstructured":"Verkhratsky A, Parpura V, Pekna M et al (2014) Glia in the pathogenesis of neurodegenerative diseases. Biochem Soc Trans 42:1291\u20131301","journal-title":"Biochem Soc Trans"},{"key":"18_CR48","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3233\/JAD-143156","volume":"45","author":"DS Bouvier","year":"2015","unstructured":"Bouvier DS, Murai KK (2015) Synergistic actions of microglia and astrocytes in the progression of Alzheimer\u2019s disease. J Alzheimers Dis 45:1001\u20131014","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"18_CR49","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1046\/j.1471-4159.1995.65062621.x","volume":"65","author":"Paolo Guidetti","year":"2002","unstructured":"Guidetti P, Eastman CL, Schwarcz R (1995) Metabolism of [5-3H]kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway. J Neurochem 65:2621\u20132632","journal-title":"Journal of Neurochemistry"},{"key":"18_CR50","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0003-9861(69)90435-4","volume":"131","author":"H Okamoto","year":"1969","unstructured":"Okamoto H, Hayaishi O (1969) Solubilization and partial purification of kynurenine hydroxylase from mitochondrial outer membrane and its electron donors. Arch Biochem Biophys 131:603\u2013608","journal-title":"Arch Biochem Biophys"},{"key":"18_CR51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2174\/187152710793237430","volume":"9","author":"MA Thevandavakkam","year":"2011","unstructured":"Thevandavakkam MA, Schwarcz R, Muchowski PJ et al (2011) Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington\u2019s disease. CNS Neurol Disord Drug Targets 9:791\u2013800","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"18_CR52","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12039","volume":"496","author":"M Amaral","year":"2013","unstructured":"Amaral M, Levy C, Heyes DJ et al (2013) Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496:382\u2013385","journal-title":"Nature"},{"key":"18_CR53","unstructured":"Giorgini F (2008) The kynurenine pathway and microglia: implications for pathology and therapy in Huntington\u2019s disease. In: Outeiro T (ed) Protein Misfolding in Biology and Disease. Transworld Research Network, Kerala, India, pp 231\u2013255"},{"key":"18_CR54","unstructured":"Sathyasaikumar KV, Severson P, West BL et al (2016) Elimination of microglia in adult mouse forebrain does not alter kynurenine 3-monooxygenase activity. Soc Neurosci Abstr 41:37:19"},{"key":"18_CR55","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/bj2830633","volume":"283","author":"MP Heyes","year":"1992","unstructured":"Heyes MP, Saito K, Markey SP (1992) Human macrophages convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J 283:633\u2013635","journal-title":"Biochem J"},{"key":"18_CR56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0021-9258(18)70659-5","volume":"28","author":"FT Castro De","year":"1957","unstructured":"De Castro FT, Brown RR, Price JM (1957) The intermediary metabolism of tryptophan by cat and rat tissue preparations. J Biol Chem 28:777\u2013784","journal-title":"J Biol Chem"},{"key":"18_CR57","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.drudis.2015.11.001","volume":"21","author":"JR Smith","year":"2016","unstructured":"Smith JR, Jamie JF, Guillemin GJ (2016) Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors. Drug Discov Today 21:315\u2013324","journal-title":"Drug Discov Today"},{"key":"18_CR58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/jm00031a015","volume":"37","author":"R Pellicciari","year":"1994","unstructured":"Pellicciari R, Natalini B, Costantino G et al (1994) Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J Med Chem 37:647\u2013655","journal-title":"J Med Chem"},{"key":"18_CR59","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00004647-199907000-00007","volume":"19","author":"A Cozzi","year":"1999","unstructured":"Cozzi A, Carpenedo R, Moroni F (1999) Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J Cereb Blood Flow Metab 19:771\u2013777","journal-title":"J Cereb Blood Flow Metab"},{"key":"18_CR60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0014-2999(96)00613-9","volume":"315","author":"C Speciale","year":"1996","unstructured":"Speciale C, Wu HQ, Cini M et al (1996) (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol 315:263\u2013267","journal-title":"Eur J Pharmacol"},{"key":"18_CR61","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/jm970467t","volume":"40","author":"S R\u00f6ver","year":"1997","unstructured":"R\u00f6ver S, Cesura AM, Huguenin P et al (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 40:4378\u20134385","journal-title":"J Med Chem"},{"key":"18_CR62","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz R, Bruno JP, Muchowski PJ et al (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465\u2013477","journal-title":"Nat Rev Neurosci"},{"key":"18_CR63","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1124\/dmd.112.046532","volume":"40","author":"MG Beconi","year":"2012","unstructured":"Beconi MG, Yates D, Lyons K et al (2012) Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048. Drug Metab Dispos 40:2297\u20132306","journal-title":"Drug Metab Dispos"},{"key":"18_CR64","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s00213-016-4384-9","volume":"233","author":"V Vengeliene","year":"2016","unstructured":"Vengeliene V, Cannella N, Takahashi T et al (2016) Metabolic shift of the kynurenine pathway impairs alcohol and cocaine seeking and relapse. Psychopharmacology 233:3449\u20133459","journal-title":"Psychopharmacology"},{"key":"18_CR65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neuropharm.2015.10.040","volume":"102","author":"E Rojewska","year":"2016","unstructured":"Rojewska E, Piotrowska A, Makuch W et al (2016) Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly reduces neuropathic pain in a rat model. Neuropharmacology 102:80\u201391","journal-title":"Neuropharmacology"},{"issue":"2","key":"18_CR66","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1471-4159.2009.05893.x","volume":"109","author":"Laura Amori","year":"2009","unstructured":"Amori L, Guidetti P, Pellicciari R et al (2009) On the relationship between the two branches of the kynurenine pathway in the rat brainin vivo. J Neurochem 109:316\u2013325","journal-title":"Journal of Neurochemistry"},{"key":"18_CR67","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jnr.21183","volume":"85","author":"G Ceresoli-Borroni","year":"2007","unstructured":"Ceresoli-Borroni G, Guidetti P, Amori L et al (2007) Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J Neurosci Res 85:845\u2013854","journal-title":"J Neurosci Res"},{"key":"18_CR68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2005.07.004","volume":"197","author":"MT Sapko","year":"2006","unstructured":"Sapko MT, Guidetti P, Yu P et al (2006) Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington\u2019s disease. Exp Neurol 197:31\u201340","journal-title":"Exp Neurol"},{"key":"18_CR69","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1021\/jm501350y","volume":"58","author":"LM Toledo-Sherman","year":"2015","unstructured":"Toledo-Sherman LM, Prime ME, Mrzljak L et al (2015) Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington\u2019s disease. J Med Chem 58:1159\u20131183","journal-title":"J Med Chem"},{"key":"18_CR70","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.4020","volume":"22","author":"DJ Mole","year":"2016","unstructured":"Mole DJ, Webster SP, Uings I et al (2016) Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis. Nat Med 22:202\u2013209","journal-title":"Nat Med"},{"key":"18_CR71","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3233\/JAD-142802","volume":"45","author":"S Bouleau","year":"2015","unstructured":"Bouleau S, Tricoire H (2015) Drosophila models of Alzheimer\u2019s disease: advances, limits, and perspectives. J Alzheimers Dis 45:1015\u20131038","journal-title":"J Alzheimers Dis"},{"key":"18_CR72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.32.812.120","volume":"32","author":"TH Morgan","year":"1910","unstructured":"Morgan TH (1910) Sex limited inheritance in Drosophila. Science 32:120\u2013122","journal-title":"Science"},{"key":"18_CR73","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1017\/S0016672300029402","volume":"57","author":"R Tearle","year":"1991","unstructured":"Tearle R (1991) Tissue specific effects of ommochrome pathway mutations in Drosophila melanogaster. Genet Res 57:257\u2013266","journal-title":"Genet Res"},{"key":"18_CR74","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1011-1344(01)00196-8","volume":"64","author":"JE Roberts","year":"2001","unstructured":"Roberts JE (2001) Ocular phototoxicity. J Photochem Photobiol B 64:136\u2013143","journal-title":"J Photochem Photobiol B"},{"key":"18_CR75","first-page":"167","volume":"85","author":"EV Savvateeva","year":"1999","unstructured":"Savvateeva EV, Popov AV, Kamyshev NG et al (1999) Age-dependent changes in memory and mushroom bodies in the Drosophila mutant vermilion deficient in the kynurenine pathway of tryptophan metabolism. Ross Fiziol Zh Im I M Sechenova 85:167\u2013183","journal-title":"Ross Fiziol Zh Im I M Sechenova"},{"key":"18_CR76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00702-009-0341-7","volume":"117","author":"GF Oxenkrug","year":"2010","unstructured":"Oxenkrug GF (2010) The extended life span of Drosophila melanogaster eye-color (white and vermilion) mutants with impaired formation of kynurenine. J Neural Transm 117:23\u201326","journal-title":"J Neural Transm"},{"key":"18_CR77","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4161\/fly.5.4.18414","volume":"5","author":"GF Oxenkrug","year":"2011","unstructured":"Oxenkrug GF, Navrotskaya V, Voroboyva L et al (2011) Extension of life span of Drosophila melanogaster by the inhibitors of tryptophan-kynurenine metabolism. Fly (Austin) 5:307\u2013309","journal-title":"Fly (Austin)"},{"key":"18_CR78","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ibmb.2015.09.009","volume":"67","author":"RA Brinzer","year":"2015","unstructured":"Brinzer RA, Henderson L, Marchiondo AA et al (2015) Metabolomic profiling of permethrin-treated Drosophila melanogaster identifies a role for tryptophan catabolism in insecticide survival. Insect Biochem Mol Biol 67:74\u201386","journal-title":"Insect Biochem Mol Biol"},{"key":"18_CR79","first-page":"93","volume":"1","author":"V Navrotskaya","year":"2015","unstructured":"Navrotskaya V, Oxenkrug G, Vorobyova L et al (2015) Attenuation of high sucrose diet-induced insulin resistance in tryptophan 2,3-dioxygenase deficient Drosophila melanogaster vermilion mutants. Integr Obes Diabetes 1:93\u201395","journal-title":"Integr Obes Diabetes"},{"key":"18_CR80","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s007020070080","volume":"107","author":"E Savvateeva","year":"2000","unstructured":"Savvateeva E, Popov A, Kamyshev N et al (2000) Age-dependent memory loss, synaptic pathology and altered brain plasticity in the Drosophila mutant cardinal accumulating 3-hydroxykynurenine. J Neural Transm 107:581\u2013601","journal-title":"J Neural Transm"},{"key":"18_CR81","first-page":"1216","volume":"44","author":"AV Popov","year":"2008","unstructured":"Popov AV, Peresleni AI, Savvateeva-Popova EV et al (2008) Effect of mutation-induced excess brain concentration of intermediates of the kynurenine pathway of tryptophan metabolism on stress resistance and courtship behavior and communicative sound production in male Drosophila melanogaster. Genetika 44:1216\u20131226","journal-title":"Genetika"},{"key":"18_CR82","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/978-1-4615-0135-0_84","volume":"527","author":"EV Savvateeva-Popova","year":"2003","unstructured":"Savvateeva-Popova EV, Popov AV, Heinemann T et al (2003) Drosophila mutants of the kynurenine pathway as a model for ageing studies. Adv Exp Med Biol 527:713\u2013722","journal-title":"Adv Exp Med Biol"},{"key":"18_CR83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0065-2806(08)60130-7","volume":"10","author":"B Linzen","year":"1974","unstructured":"Linzen B (1974) Tryptophan\u00a0\u2013 ommochrome pathway in insects. Adv Insect Physiol 10:117\u2013246","journal-title":"Adv Insect Physiol"},{"key":"18_CR84","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nature05954","volume":"448","author":"G Dietzl","year":"2007","unstructured":"Dietzl G, Chen D, Schnorrer F et al (2007) A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448:151\u2013156","journal-title":"Nature"},{"key":"18_CR85","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/genetics\/77.1.71","volume":"77","author":"S Brenner","year":"1974","unstructured":"Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77:71\u201394","journal-title":"Genetics"},{"key":"18_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1098\/rstb.1986.0056","volume":"314","author":"JG White","year":"1986","unstructured":"White JG, Southgate E, Thomson JN et al (1986) The structure of the nervous system of the nematode Caenorhabditis elegans. Philos Trans R Soc Lond Ser B Biol Sci 314:1\u2013340","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"key":"18_CR87","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/hmg\/9.6.869","volume":"9","author":"E Culetto","year":"2000","unstructured":"Culetto E, Sattelle DB (2000) A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum Mol Genet 9:869\u2013877","journal-title":"Hum Mol Genet"},{"key":"18_CR88","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806\u2013811","journal-title":"Nature"},{"key":"18_CR89","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fgene.2013.00151","volume":"4","author":"C Coburn","year":"2013","unstructured":"Coburn C, Gems D (2013) The mysterious case of the C. elegans gut granule: death fluorescence, anthranilic acid and the kynurenine pathway. Front Genet 4:151","journal-title":"Front Genet"},{"issue":"1","key":"18_CR90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00433899","volume":"135","author":"P. Babu","year":"1974","unstructured":"Babu P (1974) Biochemical genetics of Caenorhabditis elegans. Mol Gen Genet 135:39\u201344","journal-title":"Mgg Molecular & General Genetics"},{"key":"18_CR91","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/BF00268072","volume":"180","author":"SG Bhat","year":"1980","unstructured":"Bhat SG, Babu P (1980) Mutagen sensitivity of kynureninase mutants of the nematode Caenorhabditis elegans. Mol Gen Genet 180:635\u2013638","journal-title":"Mol Gen Genet"},{"key":"18_CR92","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1242\/dmm.000901","volume":"4","author":"MJ Justice","year":"2011","unstructured":"Justice MJ, Siracusa LD, Stewart AF (2011) Technical approaches for mouse models of human disease. Dis Model Mech 4:305\u2013310","journal-title":"Dis Model Mech"},{"key":"18_CR93","doi-asserted-by":"crossref","first-page":"36554","DOI":"10.1074\/jbc.M113.503813","volume":"288","author":"F Giorgini","year":"2013","unstructured":"Giorgini F, Huang SY, Sathyasaikumar KV et al (2013) Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem 288:36554\u201336566","journal-title":"J Biol Chem"},{"key":"18_CR94","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3945\/jn.112.167569","volume":"142","author":"M Terakata","year":"2012","unstructured":"Terakata M, Fukuwatari T, Sano M et al (2012) Establishment of true niacin deficiency in quinolinic acid phosphoribosyltransferase knockout mice. J Nutr 142:2148\u20132153","journal-title":"J Nutr"},{"key":"18_CR95","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-6606-2-8","volume":"2","author":"M Kanai","year":"2009","unstructured":"Kanai M, Funakoshi H, Takahashi H et al (2009) Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain 2:8","journal-title":"Mol Brain"},{"key":"18_CR96","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jri.2003.11.003","volume":"61","author":"B Baban","year":"2004","unstructured":"Baban B, Chandler P, McCool D et al (2004) Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 61:67\u201377","journal-title":"J Reprod Immunol"},{"key":"18_CR97","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neuroscience.2015.09.022","volume":"310","author":"C.M. Forrest","year":"2015","unstructured":"Forrest CM, McNair K, Pisar M et al (2015) Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine 3-monooxygenase (KMO) deletion or galantamine. Neuroscience 310:91\u2013105","journal-title":"Neuroscience"},{"issue":"10","key":"18_CR98","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.biopsych.2016.12.011","volume":"82","author":"Sophie Erhardt","year":"2017","unstructured":"Erhardt S, Pocivavsek A, Repici M et al (2017) Adaptive and behavioral changes in kynurenine 3-monooxygenase knockout mice: relevance to psychotic disorders. Biol Psychiatry 82:756\u2013765","journal-title":"Biological Psychiatry"},{"key":"18_CR99","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10163","volume":"474","author":"WC Skarnes","year":"2011","unstructured":"Skarnes WC, Rosen B, West AP et al (2011) A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474:337\u2013342","journal-title":"Nature"},{"key":"18_CR100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bbi.2015.06.022","volume":"50","author":"JM Heisler","year":"2015","unstructured":"Heisler JM, O\u2019Connor JC (2015) Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory. Brain Behav Immun 50:115\u2013124","journal-title":"Brain Behav Immun"},{"key":"18_CR101","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.200","volume":"6","author":"JM Parrott","year":"2016","unstructured":"Parrott JM, Redus L, Santana-Coelho D et al (2016) Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation. Transl Psychiatry 6:e918","journal-title":"Transl Psychiatry"},{"key":"18_CR102","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbr.2016.09.050","volume":"317","author":"T Tashiro","year":"2017","unstructured":"Tashiro T, Murakami Y, Mouri A et al (2017) Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions. Behav Brain Res 317:279\u2013285","journal-title":"Behav Brain Res"},{"key":"18_CR103","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1681\/ASN.2015070835","volume":"27","author":"R Korstanje","year":"2016","unstructured":"Korstanje R, Deutsch K, Bolanos-Palmieri P et al (2016) Loss of kynurenine 3-mono-oxygenase causes proteinuria. J Am Soc Nephrol 27:3271\u20133277","journal-title":"J Am Soc Nephrol"},{"key":"18_CR104","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.imlet.2016.11.012","volume":"181","author":"H Kubo","year":"2017","unstructured":"Kubo H, Hoshi M, Mouri A et al (2017) Absence of kynurenine 3-monooxygenase reduces mortality of acute viral myocarditis in mice. Immunol Lett 181:94\u2013100","journal-title":"Immunol Lett"},{"key":"18_CR105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.coph.2015.09.008","volume":"26","author":"R Andre","year":"2016","unstructured":"Andre R, Carty L, Tabrizi SJ (2016) Disruption of immune cell function by mutant huntingtin in Huntington\u2019s disease pathogenesis. Curr Opin Pharmacol 26:33\u201338","journal-title":"Curr Opin Pharmacol"}],"container-title":["Methods in Molecular Biology","Huntington\u2019s Disease"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7825-0_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T18:21:55Z","timestamp":1751653315000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7825-0_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493978243","9781493978250"],"references-count":105,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_18","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}